Drug intelligence / Profile preview

botulinum toxin A + botulinum toxin B

Development stage
Unknown
Lead developer
Allergan
Modality
Recombinant Proteins and Enzymes
Administration
Injectable, Intramuscular, Subcutaneous
01

Overview

Botulinum toxin A + botulinum toxin B is a combination of two neurotoxins produced by *Clostridium botulinum*. Both toxins block acetylcholine release at presynaptic cholinergic nerve terminals, but type A and type B differ in their molecular structure and substrate specificity. Botulinum toxin A products (such as onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA) and botulinum toxin B (rimabotulinumtoxinB) are used clinically for muscle spasticity, movement disorders such as cervical dystonia, cosmetic indications (wrinkles, hyperhidrosis), and some forms of bladder dysfunction. Type A cleaves the SNAP-25 protein in the SNARE complex while type B cleaves synaptobrevin (VAMP) in the same complex, both resulting in flaccid paralysis of the target muscles[3][11]. The combination would theoretically provide effects mediated by both types, but there is no approved pharmaceutical product containing both toxins in the same formulation; their use together would be off-label or investigational.

Other names
botulinum toxin type A + botulinum toxin type BBTX-A + BTX-B
02

Targets

SNAP25 (Synaptosome-associated protein 25)SV2A (Synaptic vesicle glycoprotein 2A)SYT (Synaptotagmin family)VAMP (SNARE Protein Complex)

Beyond the preview

Go deeper on botulinum toxin A + botulinum toxin B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on botulinum toxin A + botulinum toxin B.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call